CO5611148A2 - Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina - Google Patents

Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina

Info

Publication number
CO5611148A2
CO5611148A2 CO04086713A CO04086713A CO5611148A2 CO 5611148 A2 CO5611148 A2 CO 5611148A2 CO 04086713 A CO04086713 A CO 04086713A CO 04086713 A CO04086713 A CO 04086713A CO 5611148 A2 CO5611148 A2 CO 5611148A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
inhibitor
pharmaceutically acceptable
composition according
pde3
Prior art date
Application number
CO04086713A
Other languages
English (en)
Inventor
Rolf Beumne
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CO5611148A2 publication Critical patent/CO5611148A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Una composición farmacéutica que comprende, en mezcla, un primer ingrediente activo que se selecciona de un inhibidor de PDE4, un inhibidor de PDE3/4 y sus derivados farmacéuticamente aceptables, y un segundo ingrediente activo que se selecciona de un antagonista de receptor de histamina y sus derivados farmacéuticamente aceptables.2.- Una composición farmacéutica según la reivindicación 1, caracterizada porque el primer y/o segundo ingrediente activo se encuentra en la forma de una sal farmacéuticamente aceptable, solvato, N-óxido o solvato de una sal o N-óxido.3.- Una composición farmacéutica según la reivindicación 1 o 2, que es una combinación oral fija.4.- Una composición farmacéutica según la reivindicación 1 o 2, que es un polvo seco para utilizarse en un inhalador de polvo seco.5.- Una composición farmacéutica según la reivindicación 1 o 2, que es una preparación acuosa para administración nasal.6.- Una composición farmacéutica según la reivindicación 1 o 2, en la cual el inhibidor de PDE4, el inhibidor de PDE3/4 o sus derivados farmacéuticamente aceptables y el antagonista de receptor de histamina o su derivado farmacéuticamente aceptable se combina con un propulsor para formar una composición que se suministra utilizando un inhalador de dosis medida.
CO04086713A 2002-03-06 2004-09-03 Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina CO5611148A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06

Publications (1)

Publication Number Publication Date
CO5611148A2 true CO5611148A2 (es) 2006-02-28

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04086713A CO5611148A2 (es) 2002-03-06 2004-09-03 Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina

Country Status (32)

Country Link
US (1) US20050112069A1 (es)
EP (2) EP1849468B1 (es)
JP (1) JP5150034B2 (es)
KR (1) KR20040095255A (es)
CN (1) CN101257904A (es)
AR (1) AR038858A1 (es)
AT (1) ATE369134T1 (es)
AU (1) AU2003212268B2 (es)
BR (1) BR0308220A (es)
CA (1) CA2478612C (es)
CO (1) CO5611148A2 (es)
CY (2) CY1106927T1 (es)
DE (1) DE60315426T2 (es)
DK (2) DK1482938T3 (es)
EA (2) EA007903B1 (es)
ES (2) ES2400670T3 (es)
HK (1) HK1071308A1 (es)
HR (1) HRP20040909B1 (es)
IL (1) IL163336A (es)
IS (2) IS2536B (es)
MX (1) MXPA04008460A (es)
NO (1) NO335254B1 (es)
NZ (1) NZ535611A (es)
PL (1) PL211574B1 (es)
PT (2) PT1482938E (es)
RS (1) RS51018B (es)
SG (1) SG160197A1 (es)
SI (2) SI1482938T1 (es)
TW (1) TWI347845B (es)
UA (1) UA80117C2 (es)
WO (1) WO2003074055A1 (es)
ZA (1) ZA200407104B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355876B (zh) 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
JP2010513393A (ja) * 2006-12-20 2010-04-30 グラクソ グループ リミテッド Ｈ１受容体アンタゴニストとしての４−ベンジル−ｌ（２ｈ）−フタラジノン
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
LT2672957T (lt) 2011-02-07 2017-02-10 Scipharm Sarl Naujoji kompozicija, skirta cistinės fibrozės gydymui
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
US20170231931A1 (en) * 2014-08-26 2017-08-17 Fundación Para La Investigación Médica Aplicada Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
RU2673458C1 (ru) 2014-10-09 2018-11-27 Гуандун Чжуншэн Фармасьютикал Ко., Лтд Гидроксипуриновые соединения и пути их применения
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DK0706513T3 (da) * 1993-07-02 2002-09-09 Altana Pharma Ag Fluoralkoxysubstituerede benzamider og anvendelse deraf som cyklisk-nukleotid phosphodiesteraseinhibitorer
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
TR200201128T2 (tr) * 1999-10-25 2002-08-21 Byk Gulden Lomberg Chemische Fabrik Gmbh PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
EP1482938A1 (en) 2004-12-08
EA200401137A1 (ru) 2005-04-28
UA80117C2 (uk) 2007-08-27
EA007903B1 (ru) 2007-02-27
NO335254B1 (no) 2014-10-27
PT1482938E (pt) 2007-11-15
DE60315426T2 (de) 2008-07-03
EP1482938B1 (en) 2007-08-08
EA010886B1 (ru) 2008-12-30
US20050112069A1 (en) 2005-05-26
EP1849468B1 (en) 2012-12-05
HRP20040909B1 (en) 2012-11-30
WO2003074055A1 (en) 2003-09-12
JP5150034B2 (ja) 2013-02-20
CN101257904A (zh) 2008-09-03
TW200306855A (en) 2003-12-01
HK1071308A1 (en) 2005-07-15
MXPA04008460A (es) 2004-12-06
NO20044230L (no) 2004-12-06
RS51018B (sr) 2010-10-31
ES2400670T3 (es) 2013-04-11
CY1106927T1 (el) 2012-09-26
BR0308220A (pt) 2005-01-04
AR038858A1 (es) 2005-01-26
ATE369134T1 (de) 2007-08-15
PL371056A1 (en) 2005-06-13
SI1482938T1 (sl) 2007-12-31
IS8760A (is) 2008-09-04
IS7438A (is) 2004-09-03
AU2003212268B2 (en) 2008-09-11
IL163336A (en) 2009-02-11
HRP20040909A2 (en) 2005-08-31
NZ535611A (en) 2006-03-31
DK1482938T3 (da) 2007-12-03
PL211574B1 (pl) 2012-05-31
IS2536B (is) 2009-08-15
RS78004A (en) 2006-12-15
JP2005524666A (ja) 2005-08-18
EP1849468A3 (en) 2007-11-07
ZA200407104B (en) 2006-12-27
CY1113894T1 (el) 2016-07-27
EA200601592A1 (ru) 2006-12-29
CA2478612A1 (en) 2003-09-12
EP1849468A2 (en) 2007-10-31
ES2291618T3 (es) 2008-03-01
SI1849468T1 (sl) 2013-03-29
CA2478612C (en) 2013-12-10
AU2003212268A1 (en) 2003-09-16
SG160197A1 (en) 2010-04-29
DE60315426D1 (de) 2007-09-20
PT1849468E (pt) 2013-02-27
KR20040095255A (ko) 2004-11-12
TWI347845B (en) 2011-09-01
DK1849468T3 (da) 2013-02-04

Similar Documents

Publication Publication Date Title
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
CO5611148A2 (es) Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
AR055099A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
MX2010003923A (es) Formulacion farmaceutica de valsartan.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AR083422A1 (es) Composiciones y metodos para tratar la hipertension pulmonar
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
RS88404A (en) Low dose liquid entecavir formulation and use

Legal Events

Date Code Title Description
FG Application granted